Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-05-28 Environmental & Social …
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
Environmental & Social Information Classification · 99% confidence The document is a press release dated May 27, 2021, announcing that Galapagos NV will present scientific data regarding filgotinib for Rheumatoid Arthritis at the upcoming European League Against Rheumatism (EULAR) congress (June 2-5). This type of announcement, detailing upcoming presentations of scientific or clinical data at a conference, is typically classified as an Investor Presentation (IP) or a general announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing detailing a specific event like a dividend or management change, and it focuses heavily on scientific data presentation schedules, it aligns best with the Investor Presentation (IP) category, which often includes pipeline updates and scientific milestones presented to investors. It is not a Report Publication Announcement (RPA) because it is announcing *presentations* of data, not the publication of a formal company report like an Annual Report or Interim Report.
2021-05-28 English
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV, dated May 27, 2021, announcing that data regarding filgotinib for rheumatoid arthritis will be presented at the upcoming EULAR congress (June 2-5, 2021). It details the abstracts, scientific updates, safety profiles, and includes quotes from management and contact information. This format—an announcement about upcoming scientific presentations or data releases, often including context about the drug and disease—is characteristic of an Investor Presentation (IP) or a general press release related to research updates. Since it is not a formal regulatory filing (like 10-K or IR), nor a transcript (CT), nor a formal earnings release (ER), and it is a detailed communication aimed at investors and the scientific community about ongoing research and upcoming presentations, 'Investor Presentation' (IP) is the most fitting category, although it functions as a press release announcing conference participation. Given the focus on presenting scientific data and abstracts, IP is preferred over the generic RNS.
2021-05-28 English
6-K Filing
Regulatory Filings
2021-05-28 English
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
Regulatory Filings Classification · 97% confidence The document is a press release from Galapagos NV, dated May 18, 2021, announcing that the first patient has been enrolled in the FILOSOPHY Phase 4 study for Jyseleca (filgotinib) in Rheumatoid Arthritis (RA). This type of announcement, detailing the initiation of a clinical trial, the study's objectives, and providing background information on the drug and the disease, is characteristic of an announcement intended for investors and the public regarding ongoing research and development activities. It is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific financial event report (like DIV or CAP). Since it is an announcement about a clinical study and its implications, it fits best under the general category of Investor Information or a specific research update. Given the provided categories, this is a communication detailing ongoing clinical investigation and results expectations, which is often released via regulatory channels but is fundamentally an update on the company's pipeline/research. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Audit Report (AR). It is a specific announcement about a study, which is not explicitly covered by other codes like DIRS, DIV, or DEF 14A. The closest fit for a general, non-financial, non-governance, non-legal announcement that updates investors on operational progress (clinical trials) is often categorized as a Regulatory Filing (RNS) if it doesn't fit elsewhere, or potentially an Investor Presentation (IP) if it were a slide deck, but this is a press release. Since it is a formal announcement of a significant operational event (study initiation) that is not a financial result or a governance change, RNS (Regulatory Filings / General Announcement) is the most appropriate fallback, although it strongly relates to R&D progress.
2021-05-19 English
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
Regulatory Filings Classification · 93% confidence The document is a press release dated May 18, 2021, announcing that the first patient has been enrolled in the FILOSOPHY Phase 4 European real-world outcomes study for the drug Jyseleca (filgotinib). It details the study's objectives, methodology (using mobile device technology), and provides background information on Rheumatoid Arthritis and the drug itself. This type of announcement, focusing on the initiation of a clinical trial or study, does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is a specific operational update related to product development and clinical progress. Since it is a specific announcement that doesn't match the primary categories, the most appropriate classification is the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate/clinical updates, or potentially 'LTR' if it were about legal proceedings, but here it is about a study. Given the options, RNS serves as the best fit for a significant, non-financial, non-governance press release detailing clinical trial progress, as it is not a formal financial report or a specific management/board change announcement. It is not an announcement of a report being published (RPA), but the news itself.
2021-05-19 English
6-K Filing
Regulatory Filings
2021-05-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.